



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

| <i>Complete if Known</i> | |
|--------------------------|-------------------------|
| Application Number | 10/645,659 |
| Filing Date | August 22, 2003 |
| First Named Inventor | Oron YACOBY-ZEEVI et al |
| Art Unit | 1644 |
| Examiner Name | DIBRINO, MARIANNE NMN |
| Attorney Docket Number | 26128 |

1

df

2

Attorney Docket Number

26128

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional)

Applicant's unique citation designation number (optional).
2-5-11-1-1-1-SUBTGS-1-1-B

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

| Complete if Known | |
|----------------------|-------------------------|
| Application Number | 10/645,659 |
| Filing Date | August 22, 2003 |
| First Named Inventor | Oron YACOBY-ZEEVI et al |
| Group Art Unit | 1644 |
| Examiner Name | DIBRINO, MARIANNE NMN |

Sheet 2 Of 2 Attorney Docket Number 26128

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | 6 | Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174, 1995. GenBank Entry AA304653, 1997. | |
| | 7 | Agrawal "Antisense Therapeutics: Is It as Simple as Complementary Base Recognition", Molecular Medicine Today, 6: 72-81, 2002. | |
| | 8 | Branch "A Good Antisense Molecule Is Hard to Find", Trends in Biochemical Sciences, 23(2): 45-50, 1998. Abstract. | |
| | 9 | Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and Production of Recombinant Proteins", Journal of Mammary Gland Biology and Neoplasia, 3(3): 337-350, 1998. Abstract. | |
| | 10 | Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of A Bacterial Biofilm", Science, 280: 295-298, 1998. Abstract. | |
| | 11 | Kuyvenhoven et al. "Assessment of Serum Matrix Metalloproteinases MMP-2 and MMP-9 After Human Liver Transplantation: Increased Serum MMP-9 Level in Acute Rejection", Transplantation, 77(11): 1646-1652, 2004. Abstract. | |
| | 12 | Morel et al. "Human Neutrophil Gelitanase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993. | |
| | 13 | Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser, Boston, P.433, 492-495, 1994. | |
| | 14 | Quax et al. "Metastatic Behavior of Human Melanoma Cell Lines in Nude Mice Correlates With Urokinase-Type Plasminogen Activator, Its Type-I Inhibitor, and Urokinase-Mediated Matrix Degradation", The Journal of Cell Biology, 115(1): 191-199, 1991. | |
| | 15 | Savion et al. "Murine Macrophage Heparanase: Inhibition and Comparison With Metastatic Tumor Cells", Journal of Cellular Physiology, 130: 77-84, 1987. | |
| | 16 | Sordat et al. "Modulation of the Malignant Phenotype With the Urokinase-Type Plasminogen Activator and the Type I Plasminogen Activator Inhibitor", Cell Differentiation and Development, 32: 277-286, 1990. | |
| | 17 | Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, 1999. | |
| Examiner Signature | | Date Considered | |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box